{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:09:25Z","timestamp":1789646965077,"version":"4.0.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is an innovative lipid parameter for atherosclerosis risk, yet its association with major adverse cardiovascular events (MACE) in peripheral artery disease (PAD) patients remains unclear. We retrospectively analyzed 13,224 PAD patients in Hong Kong, assessing baseline NHHR and longitudinal NHHR trajectories as predictors of MACE using spline models, latent class growth modeling, and Cox proportional hazards models. Over a median follow-up of 3.4 years, a U-shaped relationship emerged between baseline NHHR and MACE risk. Patients in the highest quintile of NHHR (Q5) had a significantly increased risk of MACE (HR\u2009=\u20091.16, 95% CI: 1.07\u20131.25, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), as did those in the lowest quintile (Q1) (HR\u2009=\u20091.17, 95% CI: 1.08\u20131.27, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), compared with the reference group. Among five NHHR trajectories, moderate-high-stable (HR\u2009=\u20091.17 [95% CI: 1.04\u20131.32], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and high-stable groups (HR\u2009=\u20091.35 [95% CI: 1.14\u20131.60], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) showed higher risk, whereas the declining group had no increased risk (HR\u2009=\u20091.04 [95% CI: 0.88\u20131.23], <jats:italic>P<\/jats:italic>\u2009=\u20090.356). High and low baseline NHHR, as well as persistently elevated trajectories, were associated with higher MACE risk in PAD, whereas declining trajectories normalized this risk. NHHR may serve as a useful marker for cardiovascular risk stratification in PAD patients.<\/jats:p>","DOI":"10.1038\/s41598-025-19856-0","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:53:23Z","timestamp":1760525603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baseline and longitudinal patterns of Non-HDL-C to HDL-C ratio (NHHR) and major adverse cardiovascular events in peripheral artery disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Yujia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoudong","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuangMing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"10","key":"19856_CR1","doi-asserted-by":"publisher","first-page":"e1553","DOI":"10.1016\/S2214-109X(23)00355-8","volume":"11","author":"Global burden of peripheral artery disease and its risk factors","year":"2023","unstructured":"Global burden of peripheral artery disease and its risk factors. 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Glob Health. 11 (10), e1553\u2013e1565 (2023).","journal-title":"Lancet Glob Health"},{"issue":"8","key":"19856_CR2","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","volume":"7","author":"P Song","year":"2019","unstructured":"Song, P. et al. Global, regional, and National prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 7 (8), e1020\u2013e1030 (2019).","journal-title":"Lancet Glob Health"},{"issue":"9901","key":"19856_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FG Fowkes","year":"2013","unstructured":"Fowkes, F. G. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382 (9901), 1329\u20131340 (2013).","journal-title":"Lancet"},{"issue":"4","key":"19856_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca, M. P. et al. Low-Density lipoprotein cholesterol Lowering with Evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further cardiovascular outcomes research with PCSK9 Inhibition in subjects with elevated Risk). Circulation 137 (4), 338\u2013350 (2018).","journal-title":"Circulation"},{"issue":"21","key":"19856_CR5","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca, M. P. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl. J. Med. 382 (21), 1994\u20132004 (2020).","journal-title":"N Engl. J. Med."},{"issue":"12","key":"19856_CR6","first-page":"e686","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman, M. D. et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: A report of the American college of cardiology\/american heart association task force on clinical practice guidelines. Circulation 135 (12), e686\u2013e725 (2017).","journal-title":"Circulation"},{"key":"19856_CR7","doi-asserted-by":"crossref","unstructured":"de Oliveira, L. L. H., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L. & Soares, P. R. Dyslipidemia: A narrative review on pharmacotherapy. Pharmaceuticals (Basel) 17(3), 289 (2024).","DOI":"10.3390\/ph17030289"},{"issue":"16","key":"19856_CR8","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/eurheartj\/ehac783","volume":"44","author":"PE St\u00fcrzebecher","year":"2023","unstructured":"St\u00fcrzebecher, P. E., Katzmann, J. L. & Laufs, U. What is \u2018remnant cholesterol\u2019? Eur. Heart J. 44 (16), 1446\u20131448 (2023).","journal-title":"Eur. Heart J."},{"issue":"6","key":"19856_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/MOL.0000000000000237","volume":"26","author":"R Verbeek","year":"2015","unstructured":"Verbeek, R., Hovingh, G. K. & Boekholdt, S. M. Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr. Opin. Lipidol. 26 (6), 502\u2013510 (2015).","journal-title":"Curr. Opin. Lipidol."},{"issue":"8","key":"19856_CR10","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.amjcard.2017.01.008","volume":"119","author":"G Harari","year":"2017","unstructured":"Harari, G., Green, M. S., Magid, A. & Zelber-Sagi, S. Usefulness of Non-High-Density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-Year Follow-Up. Am. J. Cardiol. 119 (8), 1193\u20131198 (2017).","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"19856_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"DM Lloyd-Jones","year":"2016","unstructured":"Lloyd-Jones, D. M. et al. 2016 ACC expert consensus decision pathway on the role of Non-Statin therapies for LDL-Cholesterol Lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American college of cardiology task force on clinical expert consensus documents. J. Am. Coll. Cardiol. 68 (1), 92\u2013125 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"19856_CR12","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/DMSO.S355980","volume":"15","author":"G Sheng","year":"2022","unstructured":"Sheng, G. et al. Utility of Non-High-Density lipoprotein cholesterol to High-Density lipoprotein cholesterol ratio in evaluating incident diabetes risk. Diabetes Metab. Syndr. Obes. 15, 1677\u20131686 (2022).","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"9","key":"19856_CR13","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2337\/dc11-0209","volume":"34","author":"B Eliasson","year":"2011","unstructured":"Eliasson, B. et al. Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National diabetes register. Diabetes Care. 34 (9), 2095\u20132100 (2011).","journal-title":"Diabetes Care"},{"issue":"10","key":"19856_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.5603\/KP.a2015.0086","volume":"73","author":"L Zhu","year":"2015","unstructured":"Zhu, L. et al. Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people. Kardiol Pol. 73 (10), 931\u2013938 (2015).","journal-title":"Kardiol Pol."},{"issue":"1","key":"19856_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12944-023-01939-4","volume":"22","author":"W Lin","year":"2023","unstructured":"Lin, W. et al. Association between the non-HDL-cholesterol to HDL- cholesterol ratio and abdominal aortic aneurysm from a Chinese screening program. Lipids Health Dis. 22 (1), 187 (2023).","journal-title":"Lipids Health Dis."},{"issue":"1","key":"19856_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/bmm-2022-0548","volume":"17","author":"Q Mao","year":"2023","unstructured":"Mao, Q., Zhao, J. & Zhao, X. Association of non-HDL-C-to-HDL-C ratio with coronary lesions and its prognostic performance in first-onset NSTEMI. Biomark. Med. 17 (1), 29\u201339 (2023).","journal-title":"Biomark. Med."},{"issue":"3","key":"19856_CR17","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1016\/j.ijcard.2013.03.027","volume":"168","author":"SW Kim","year":"2013","unstructured":"Kim, S. W. et al. Non-HDL-cholesterol\/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than Apolipoprotein b\/apolipoprotein A1. Int. J. Cardiol. 168 (3), 2678\u20132683 (2013).","journal-title":"Int. J. Cardiol."},{"issue":"12","key":"19856_CR18","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1111\/jgh.15664","volume":"36","author":"JC Lai","year":"2021","unstructured":"Lai, J. C. et al. Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135 395 patients from 2000 to 2017. J. Gastroenterol. Hepatol. 36 (12), 3487\u20133499 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"19856_CR19","doi-asserted-by":"crossref","unstructured":"Schubert J, Leosdottir M, Lindahl B, Melhus H, Westerbergh J, Modica A, Hagstr\u00f6m E:Association between non\u2013high-density lipoprotein cholesterol change and major adverse outcomes after myocardial infarction. Atherosclerosis 2023, 379:S56.","DOI":"10.1016\/j.atherosclerosis.2023.06.836"},{"issue":"6","key":"19856_CR20","doi-asserted-by":"publisher","first-page":"e015355","DOI":"10.1161\/JAHA.119.015355","volume":"9","author":"J Golledge","year":"2020","unstructured":"Golledge, J. et al. Association of serum lipoprotein (a) with the requirement for a peripheral artery operation and the incidence of major adverse cardiovascular events in people with peripheral artery disease. J. Am. Heart Assoc. 9 (6), e015355 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"19856_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2022.10.002","volume":"363","author":"B Zierfuss","year":"2022","unstructured":"Zierfuss, B. et al. Lipoprotein (a) and long-term outcome in patients with peripheral artery disease undergoing revascularization. Atherosclerosis 363, 94\u2013101 (2022).","journal-title":"Atherosclerosis"},{"key":"19856_CR22","doi-asserted-by":"publisher","first-page":"745742","DOI":"10.1155\/2013\/745742","volume":"2013","author":"L Meira-Machado","year":"2013","unstructured":"Meira-Machado, L., Cadarso-Su\u00e1rez, C., Gude, F. & Ara\u00fajo, A. SmoothHR: an R package for Pointwise nonparametric Estimation of hazard ratio curves of continuous predictors. Comput. Math. Methods Med. 2013, 745742 (2013).","journal-title":"Comput. Math. Methods Med."},{"issue":"3","key":"19856_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0049124101029003005","volume":"29","author":"BL Jones","year":"2001","unstructured":"Jones, B. L., Nagin, D. S. & Roeder, K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol. Methods Res. 29 (3), 374\u2013393 (2001).","journal-title":"Sociol. Methods Res."},{"key":"19856_CR24","doi-asserted-by":"crossref","unstructured":"Nagin, D. S. 1. Introduction and rationale. In Group-Based Modeling of Development. (ed.Nagin, D.S.) 1\u201320 (Harvard University Press, 2005).","DOI":"10.4159\/9780674041318"},{"key":"19856_CR25","doi-asserted-by":"crossref","unstructured":"You, J., Wang, Z., Lu, G. & Chen, Z. Association between the Non-high-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio and the Risk of Coronary Artery Disease. Biomed Res Int 2020:7146028. (2020).","DOI":"10.1155\/2020\/7146028"},{"issue":"1","key":"19856_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12944-024-02309-4","volume":"23","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study. Lipids Health Dis. 23 (1), 324 (2024).","journal-title":"Lipids Health Dis."},{"key":"19856_CR27","doi-asserted-by":"crossref","unstructured":"Evsen, A., Aktan, A., Altunova, M. & \u00d6zbek, M. Is plasma atherogenic index or LDL\/HDL ratio more predictive of peripheral arterial disease complexity? Vascular.33(3), 648\u2013653 (2025).","DOI":"10.1177\/17085381241260203"},{"issue":"24","key":"19856_CR28","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n, J. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel. Eur. Heart J. 41 (24), 2313\u20132330 (2020).","journal-title":"Eur. Heart J."},{"key":"19856_CR29","doi-asserted-by":"publisher","first-page":"931931","DOI":"10.3389\/fphys.2022.931931","volume":"13","author":"YN Qiao","year":"2022","unstructured":"Qiao, Y. N., Zou, Y. L. & Guo, S. D. Low-density lipoprotein particles in atherosclerosis. Front. Physiol. 13, 931931 (2022).","journal-title":"Front. Physiol."},{"issue":"7293","key":"19856_CR30","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (7293), 1357\u20131361 (2010).","journal-title":"Nature"},{"key":"19856_CR31","doi-asserted-by":"publisher","first-page":"925923","DOI":"10.3389\/fcvm.2022.925923","volume":"9","author":"H Jiang","year":"2022","unstructured":"Jiang, H. et al. Mechanisms of oxidized LDL-Mediated endothelial dysfunction and its consequences for the development of atherosclerosis. Front. Cardiovasc. Med. 9, 925923 (2022).","journal-title":"Front. Cardiovasc. Med."},{"issue":"47","key":"19856_CR32","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg, H. N. et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European atherosclerosis society. Eur. Heart J. 42 (47), 4791\u20134806 (2021).","journal-title":"Eur. Heart J."},{"issue":"18","key":"19856_CR33","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","volume":"81","author":"TC Gilliland","year":"2023","unstructured":"Gilliland, T. C. et al. Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes. J. Am. Coll. Cardiol. 81 (18), 1780\u20131792 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"19856_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","volume":"16","author":"MB Boffa","year":"2019","unstructured":"Boffa, M. B. & Koschinsky, M. L. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat. Rev. Cardiol. 16 (5), 305\u2013318 (2019).","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"19856_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0021-9150(99)00065-9","volume":"144","author":"O Stein","year":"1999","unstructured":"Stein, O. & Stein, Y. Atheroprotective mechanisms of HDL. Atherosclerosis 144 (2), 285\u2013301 (1999).","journal-title":"Atherosclerosis"},{"issue":"39","key":"19856_CR36","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","volume":"45","author":"J Schubert","year":"2024","unstructured":"Schubert, J. et al. Intensive early and sustained Lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the Swedeheart registry. Eur. Heart J. 45 (39), 4204\u20134215 (2024).","journal-title":"Eur. Heart J."},{"issue":"7","key":"19856_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","volume":"3","author":"D Saleheen","year":"2015","unstructured":"Saleheen, D. et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 3 (7), 507\u2013513 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"32","key":"19856_CR38","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen, C. M., Varbo, A. & Nordestgaard, B. G. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur. Heart J. 38 (32), 2478\u20132486 (2017).","journal-title":"Eur. Heart J."},{"issue":"4","key":"19856_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrcardio.2010.222","volume":"8","author":"M Navab","year":"2011","unstructured":"Navab, M., Reddy, S. T., Van Lenten, B. J. & Fogelman, A. M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8 (4), 222\u2013232 (2011).","journal-title":"Nat. Rev. Cardiol."},{"issue":"6278","key":"19856_CR40","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"Zanoni, P. et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351 (6278), 1166\u20131171 (2016).","journal-title":"Science"},{"key":"19856_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.phrs.2017.02.008","volume":"119","author":"S Ganjali","year":"2017","unstructured":"Ganjali, S. et al. Effects of Curcumin on HDL functionality. Pharmacol. Res. 119, 208\u2013218 (2017).","journal-title":"Pharmacol. Res."},{"issue":"8","key":"19856_CR42","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1210\/jc.2018-02511","volume":"104","author":"ZH Li","year":"2019","unstructured":"Li, Z. H. et al. High-Density lipoprotein cholesterol and All-Cause and Cause-Specific mortality among the elderly. J. Clin. Endocrinol. Metab. 104 (8), 3370\u20133378 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"19856_CR43","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1161\/ATVBAHA.112.248617","volume":"32","author":"CY Huang","year":"2012","unstructured":"Huang, C. Y. et al. Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating Rho-associated kinase pathways. Arterioscler. Thromb. Vasc Biol. 32 (10), 2405\u20132417 (2012).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"2","key":"19856_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/02813432.2010.487371","volume":"28","author":"P Tuikkala","year":"2010","unstructured":"Tuikkala, P. et al. Serum total cholesterol levels and all-cause mortality in a home-dwelling elderly population: a six-year follow-up. Scand. J. Prim. Health Care. 28 (2), 121\u2013127 (2010).","journal-title":"Scand. J. Prim. Health Care"},{"issue":"1","key":"19856_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12916-024-03536-3","volume":"22","author":"B Yu","year":"2024","unstructured":"Yu, B. et al. The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) as a predictor of all-cause and cardiovascular mortality in US adults with diabetes or prediabetes: NHANES 1999\u20132018. BMC Med. 22 (1), 317 (2024).","journal-title":"BMC Med."},{"key":"19856_CR46","doi-asserted-by":"publisher","first-page":"903481","DOI":"10.3389\/fcvm.2022.903481","volume":"9","author":"RX Zeng","year":"2022","unstructured":"Zeng, R. X. et al. U-Shaped relationship of Non-HDL cholesterol with All-Cause and cardiovascular mortality in men without Statin therapy. Front. Cardiovasc. Med. 9, 903481 (2022).","journal-title":"Front. Cardiovasc. Med."},{"issue":"7","key":"19856_CR47","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamacardio.2022.0912","volume":"7","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Association between High-Density lipoprotein cholesterol levels and adverse cardiovascular outcomes in High-risk populations. JAMA Cardiol. 7 (7), 672\u2013680 (2022).","journal-title":"JAMA Cardiol."},{"issue":"19","key":"19856_CR48","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","volume":"68","author":"DT Ko","year":"2016","unstructured":"Ko, D. T. et al. High-Density lipoprotein cholesterol and Cause-Specific mortality in individuals without previous cardiovascular conditions: the CANHEART study. J. Am. Coll. Cardiol. 68 (19), 2073\u20132083 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"19856_CR49","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2147\/CIA.S271528","volume":"15","author":"YQ Huang","year":"2020","unstructured":"Huang, Y. Q. et al. The U shaped relationship between High-Density lipoprotein cholesterol and All-Cause or Cause-Specific mortality in adult population. Clin. Interv Aging. 15, 1883\u20131896 (2020).","journal-title":"Clin. Interv Aging"},{"key":"19856_CR50","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.2147\/RMHP.S272624","volume":"13","author":"CL Chen","year":"2020","unstructured":"Chen, C. L. et al. U-Shaped association of High-Density lipoprotein cholesterol with All-Cause and cardiovascular mortality in hypertensive population. Risk Manag Healthc. Policy. 13, 2013\u20132025 (2020).","journal-title":"Risk Manag Healthc. Policy"},{"issue":"1","key":"19856_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12944-024-02343-2","volume":"23","author":"Y Cui","year":"2024","unstructured":"Cui, Y. & Choi, M. Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and angina pectoris in US adults: a cross-sectional retrospective study based on NHANES 2009\u20132018. Lipids Health Dis. 23 (1), 347 (2024).","journal-title":"Lipids Health Dis."},{"issue":"20","key":"19856_CR52","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1161\/01.CIR.0000038496.57570.06","volume":"106","author":"V Bittner","year":"2002","unstructured":"Bittner, V. et al. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the bypass angioplasty revascularization investigation (BARI). Circulation 106 (20), 2537\u20132542 (2002).","journal-title":"Circulation"},{"issue":"11","key":"19856_CR53","doi-asserted-by":"publisher","first-page":"e1176","DOI":"10.1212\/WNL.0000000000007091","volume":"92","author":"E Valdes-Marquez","year":"2019","unstructured":"Valdes-Marquez, E. et al. Relative effects of LDL-C on ischemic stroke and coronary disease: A Mendelian randomization study. Neurology 92 (11), e1176\u2013e1187 (2019).","journal-title":"Neurology"},{"issue":"1","key":"19856_CR54","first-page":"37","volume":"38","author":"HX Ma","year":"2025","unstructured":"Ma, H. X., Chen, H. Q. & Wang, P. C. Association between Non-high-density lipoprotein cholesterol to High-density lipoprotein cholesterol ratio (NHHR) and stroke among adults in the USA: A Cross-Sectional NHANES study. Biomed. Environ. Sci. 38 (1), 37\u201346 (2025).","journal-title":"Biomed. Environ. Sci."},{"issue":"1","key":"19856_CR55","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/dom.16018","volume":"27","author":"M Liu","year":"2025","unstructured":"Liu, M. et al. Association of non-high-density lipoprotein cholesterol\/high-density lipoprotein cholesterol ratio with cardiovascular outcomes in patients with type 2 diabetes mellitus: evidence from the ACCORD cohort. Diabetes Obes. Metab. 27 (1), 300\u2013311 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"19856_CR56","doi-asserted-by":"publisher","first-page":"1500025","DOI":"10.3389\/fcvm.2024.1500025","volume":"11","author":"L Liu","year":"2024","unstructured":"Liu, L. et al. Association of cumulative non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with the risk of cardiometabolic disease. Front. Cardiovasc. Med. 11, 1500025 (2024).","journal-title":"Front. Cardiovasc. Med."},{"issue":"10215","key":"19856_CR57","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","volume":"394","author":"FJ Brunner","year":"2019","unstructured":"Brunner, F. J. et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the multinational cardiovascular risk consortium. Lancet 394 (10215), 2173\u20132183 (2019).","journal-title":"Lancet"},{"issue":"11","key":"19856_CR58","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray, K. K. et al. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study. Eur. J. Prev. Cardiol. 28 (11), 1279\u20131289 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"19856_CR59","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray, K. K. et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg. Health Eur. 29, 100624 (2023).","journal-title":"Lancet Reg. Health Eur."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19856-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19856-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19856-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:04:14Z","timestamp":1760529854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19856-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19856"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19856-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35993"}}